Loading
Treatment that starves cancers which grow in response to a hormone, mainly oestrogen in breast cancer and testosterone in prostate cancer, by lowering the hormone or blocking its receptor.
About 70% of breast cancers carry the oestrogen receptor and most prostate cancers depend on the androgen receptor; drugs either stop the hormone being made (aromatase inhibitors, GnRH analogues, abiraterone) or block the receptor (tamoxifen, fulvestrant, enzalutamide), and newer agents degrade the receptor outright (elacestrant, vepdegestrant). Hormone therapy is given as tablets or injections for years, has fewer acute side effects than chemotherapy, and prevents many recurrences; its limits are resistance, when the tumour mutates the receptor or bypasses it (hence combining with CDK4/6, PI3K or AKT inhibitors), and long-term effects on bone, mood, and sexual function. 'Castration-resistant' prostate cancer is disease that keeps growing despite testosterone suppression.
In plain words · The hormone switch that drives most breast cancers. Blocking or destroying it is the oldest and most effective targeted therapy.
Showing the target this term concerns: Estrogen receptor (ERα).
Shares SPCG-7/SFUO-3, GETUG-AFU 15, HERO, RTOG 94-08.
Shares RTOG 94-08, EORTC 22863, DART 01/05 GICOR, Androgen deprivation & AR pathway inhibitors.
Shares Agonist and antagonist, Targeted therapy, Palbociclib, CDK4/6 inhibitors.
Shares SPCG-7/SFUO-3, DART 01/05 GICOR, RTOG 92-02, Androgen deprivation & AR pathway inhibitors.
Shares Oestrogen receptor signalling, Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs).
Shares HERO, What androgen deprivation costs: the side of hormone therapy the survival curves do not show, Androgen receptor signalling, Androgen deprivation & AR pathway inhibitors.
Shares SPCG-7/SFUO-3, RTOG 94-08, EORTC 22961, EORTC 22863.
Shares CDK4/6, Palbociclib, Estrogen receptor (ERα), CDK4/6 inhibitors.